Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER studyDavid M. Ross, Timothy P. Hughes, Anthony P. Schwarer et al.|Blood|2013Cited by 705
Long-term treatment-free remission of chronic myeloid leukemia with falling levels of residual leukemic cellsTimothy P. Hughes, David T Yeung, Susan Branford et al.|Leukemia|2018Cited by 78
High prevalence of relapse in children with Philadelphia-like acute lymphoblastic leukemia despite risk-adapted treatmentSusan L. Heatley, Deborah L. White, Michael Osborn et al.|Haematologica|2017Cited by 62
Lineage of measurable residual disease in patients with chronic myeloid leukemia in treatment-free remissionIlaria S. Pagani, David M. Ross, David T Yeung et al.|Leukemia|2019Cited by 51
Gene expression signature that predicts early molecular response failure in chronic-phase CML patients on frontline imatinibChung Hoow Kok, Timothy P. Hughes, David T Yeung et al.|Blood Advances|2019Cited by 43